CD4 and inflammatory bowel disease: Analysis of the adhesion of CD4+ T cells to MAdCAM-1 on a functional level with dynamic adhesion assays in IBD patients prior to the start of treatment appears to be a promising tool for the identification of patients, which are likely to respond to therapy with vedolizumab.